Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149359 | 0.93 | PARP1 (0.48) | PPARGPPARAHTR7PARP1HTR1A | |
| Xaliproden SCHEMBL137094 | 0.86 | SIGMAR1 (0.51) | PPARGPPARAHTR7PARP1HTR1A | |
| Xaliproden SCHEMBL29377982 | 0.86 | SIGMAR1 (0.51) | PPARGPPARAHTR7PARP1HTR1A | |
| Xaliproden SCHEMBL29393004 | 0.85 | SIGMAR1 (0.50) | PPARGPPARAHTR7PARP1HTR1A | |
| Xaliproden SCHEMBL116721 | 0.85 | SIGMAR1 (0.50) | PPARGPPARAHTR7PARP1HTR1A | |
| Xaliproden SCHEMBL1650254 | 0.84 | SIGMAR1 (0.52) | PPARGPPARAHTR7PARP1HTR1A | |
| SCHEMBL5149422 | 0.84 | DRD4 (0.49) | PPARGPPARAHTR7PARP1HTR1A | |
| SCHEMBL4587500 | 0.83 | HTR7 (0.52) | PPARGPPARAHTR7PARP1DRD2 | |
| SCHEMBL5149448 | 0.83 | PPARG (0.47) | PPARGPPARAHTR7PARP1HTR1A | |
| SCHEMBL9366593 | 0.83 | PPARG (0.51) | PPARGPPARAHTR7PARP1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383762-B1 | TETRAHYDROPYRIDYL-ALKYL-HETEROCYCLES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-06-20 | — | — | EP | claimed |
| US-7186720-B2 | Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same | SANOFI-AVENTIS (FR) | 2007-03-06 | — | — | US | claimed |
| US-20040138264-A1 | Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1383762-B1 | TETRAHYDROPYRIDYL-ALKYL-HETEROCYCLES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-06-20 | — | — | EP | disclosed |
| US-7186720-B2 | Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same | SANOFI-AVENTIS (FR) | 2007-03-06 | — | — | US | disclosed |
| US-20040138264-A1 | Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-07-15 | — | — | US | disclosed |
| EP-1383762-A1 | TETRAHYDROPYRIDYL-ALKYL-HETEROCYCLES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002085888-A1 | TETRAHYDROPYRIDYL-ALKYL-HETEROCYCLES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138264-A1 | Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same | CYP2F1, CYP11B1, CYP11B2 | PPARG 1525/4885PPARA 1964/4885HTR7 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.